NCCTG
NORTH CENTRAL CANCER TREATMENT GROUP

Date: March 16, 2007

To: NCCTG Primary Clinical Research Associates

From: Janis Wobschall
Protocol Development Coordinator

Re: N027D, A Phase I Study of CCI-779 and Temozolomide in Combination with Radiation Therapy in Glioblastoma Multiforme

The following forms have been revised:

- Baseline Tissue Specimen Submission Form (revised to remove reference "Frozen Tissue" section and added "Date Sent" for Paraffin Block section)
- MTD Patients Active Monitoring Blood Specimen Submission Form (has been renamed to "MAYO CLINIC ROCHESTER ONLY AT MTD;" cycle 1 reference changed to cycle 1 or 8)

The All Patients Active Monitoring Blood Specimen Submission Form has been deleted.

If you have any questions, please feel free to contact me at 507/266-3549.

JW/dg
Enclosure